Format
Sort by
Items per page

Send to

Choose Destination

Best matches for herpes zoster disease AND postherpetic neuralgia AND vaccination AND vaccines:

[Zoster and postherpetic neuralgia: vaccine prevention is available]. Belmin J et al. Geriatr Psychol Neuropsychiatr Vieil. (2015)

Zoster vaccine (Zostavax): a review of its use in preventing herpes zoster and postherpetic neuralgia in older adults. Sanford M et al. Drugs Aging. (2010)

Vaccination against Herpes Zoster and Postherpetic Neuralgia. Oxman MN et al. J Infect Dis. (2008)

Search results

Items: 1 to 20 of 121

1.

Post-herpetic neuralgia - a review of current management and future directions.

Schutzer-Weissmann J, Farquhar-Smith P.

Expert Opin Pharmacother. 2017 Nov;18(16):1739-1750. doi: 10.1080/14656566.2017.1392508. Epub 2017 Oct 26. Review.

PMID:
29025327
2.

[Protection from a dormant time bomb: The development of effective vaccines against herpes zoster].

Schelling J, Rückert-Eheberg IM, Leischker AH.

MMW Fortschr Med. 2017 Jun;159(10):46-48. doi: 10.1007/s15006-017-9707-1. Review. German. No abstract available.

PMID:
28550546
3.

Cost-effectiveness of varicella vaccine against herpes zoster and post-herpetic neuralgia for elderly in Japan.

Hoshi SL, Kondo M, Okubo I.

Vaccine. 2017 May 31;35(24):3264-3271. doi: 10.1016/j.vaccine.2017.04.046. Epub 2017 May 4.

PMID:
28479176
4.

Effectiveness and Duration of Protection Provided by the Live-attenuated Herpes Zoster Vaccine in the Medicare Population Ages 65 Years and Older.

Izurieta HS, Wernecke M, Kelman J, Wong S, Forshee R, Pratt D, Lu Y, Sun Q, Jankosky C, Krause P, Worrall C, MaCurdy T, Harpaz R.

Clin Infect Dis. 2017 Mar 15;64(6):785-793. doi: 10.1093/cid/ciw854.

PMID:
28362955
5.

Looking back to move forward: a twenty-year audit of herpes zoster in Asia-Pacific.

Chen LK, Arai H, Chen LY, Chou MY, Djauzi S, Dong B, Kojima T, Kwon KT, Leong HN, Leung EM, Liang CK, Liu X, Mathai D, Pan JY, Peng LN, Poblete ER, Poi PJ, Reid S, Tantawichien T, Won CW.

BMC Infect Dis. 2017 Mar 15;17(1):213. doi: 10.1186/s12879-017-2198-y. Review.

6.

Prevention of herpes zoster and its complications: from the clinic to the real-life experience with the vaccine.

Giovanni G, Nicoletta V, Parvanè K, Silvia L, Armando S.

J Med Microbiol. 2016 Dec;65(12):1363-1369. doi: 10.1099/jmm.0.000386. Epub 2016 Nov 4. Review.

PMID:
27902409
7.

COST-EFFECTIVENESS ANALYSIS OF HERPES ZOSTER VACCINATION IN ITALIAN ELDERLY PERSONS.

Coretti S, Codella P, Romano F, Ruggeri M, Cicchetti A.

Int J Technol Assess Health Care. 2016 Jan;32(4):233-240. Epub 2016 Sep 14.

PMID:
27624398
8.

Cost-effectiveness of a herpes zoster vaccination program among the French elderly people.

Belchior E, Lévy-Bruhl D, Le Strat Y, Herida M.

Hum Vaccin Immunother. 2016 Sep;12(9):2378-82. doi: 10.1080/21645515.2016.1184801. Epub 2016 Aug 2.

9.

Budget-Impact Analysis of Alternative Herpes Zoster Vaccine Strategies: A U.S. HMO Perspective.

Graham J, Mauskopf J, Kawai K, Johnson KD, Xu R, Acosta CJ.

J Manag Care Spec Pharm. 2016 Jul;22(7):872-88. doi: 10.18553/jmcp.2016.22.7.872.

10.

Quantification of risk factors for postherpetic neuralgia in herpes zoster patients: A cohort study.

Forbes HJ, Bhaskaran K, Thomas SL, Smeeth L, Clayton T, Mansfield K, Minassian C, Langan SM.

Neurology. 2016 Jul 5;87(1):94-102. doi: 10.1212/WNL.0000000000002808. Epub 2016 Jun 10.

11.

Real-World Effectiveness and Safety of a Live-Attenuated Herpes Zoster Vaccine: A Comprehensive Review.

Ansaldi F, Trucchi C, Alicino C, Paganino C, Orsi A, Icardi G.

Adv Ther. 2016 Jul;33(7):1094-104. doi: 10.1007/s12325-016-0355-0. Epub 2016 Jun 4. Review.

12.

[Zoster and postherpetic neuralgia: vaccine prevention is available].

Belmin J, Jarzebowski W, Lafuente-Lafuente C.

Geriatr Psychol Neuropsychiatr Vieil. 2015 Sep;13 Suppl 2:15-20. doi: 10.1684/pnv.2015.0538. Review. French.

PMID:
26967927
13.

The use of Zostavax in Spain: the economic case for vaccination of individuals aged 50 years and older.

Lopez-Belmonte JL, Cisterna R, Gil de Miguel A, Guilmet C, Bianic F, Uhart M.

J Med Econ. 2016 Jun;19(6):576-86. doi: 10.3111/13696998.2016.1146726. Epub 2016 Mar 2.

PMID:
26808422
14.

Herpes Zoster Vaccine in the Long-Term Care Setting: A Clinical and Logistical Conundrum.

Schafer KM, Reidt S.

Consult Pharm. 2016 Jan;31(1):33-7. doi: 10.4140/TCP.n.2016.33.

PMID:
26803085
15.

Review of the Persistence of Herpes Zoster Vaccine Efficacy in Clinical Trials.

Cook SJ, Flaherty DK.

Clin Ther. 2015 Nov 1;37(11):2388-97. doi: 10.1016/j.clinthera.2015.09.019. Epub 2015 Oct 23. Review.

PMID:
26602282
16.

[Practical references for Herpes zoster vaccination].

[No authors listed]

MMW Fortschr Med. 2015 Aug 20;157(14):75. German. No abstract available.

PMID:
26554071
17.

Herpes zoster epidemiology, management, and disease and economic burden in Europe: a multidisciplinary perspective.

Johnson RW, Alvarez-Pasquin MJ, Bijl M, Franco E, Gaillat J, Clara JG, Labetoulle M, Michel JP, Naldi L, Sanmarti LS, Weinke T.

Ther Adv Vaccines. 2015 Jul;3(4):109-20. doi: 10.1177/2051013615599151. Review. Erratum in: Ther Adv Vaccines. 2016 Jan;4(1-2):32.

18.

Cost-Effectiveness of Herpes Zoster Vaccine for Persons Aged 50 Years.

Le P, Rothberg MB.

Ann Intern Med. 2015 Oct 6;163(7):489-97. doi: 10.7326/M15-0093.

PMID:
26344036
19.

[Vaccination against Herpes Zoster after 50 years-of-age is effective].

[No authors listed]

MMW Fortschr Med. 2015 Aug 20;157(14):74-5. doi: 10.1007/s15006-015-3380-z. German. No abstract available.

PMID:
26289853
20.

Supplemental Content

Loading ...
Support Center